Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico
Open Access
- 31 March 2020
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (8), 1828-1834
- https://doi.org/10.1111/jdv.16402
Abstract
Background At the dermatology service of the General Hospital of Mexico City, Mexico, two patients, father and son, with black‐grain mycetoma were seen. The grains were isolated and the cultured fungi were identified as Madurella mycetomatis based on morphology. Using the M. mycetomatis specific PCR, amplicons of a different size than that of the M. mycetomatis type strain were obtained. Objective To determine the causative agent of the two black‐grain mycetoma cases and develop non‐culture based diagnostic tools to identify them to the species level Methods The M. mycetomatis specific, the internal transcribed spacer (ITS) region, β‐tubulin (BT) and ribosomal binding protein 2 (RBP2) PCRs were used to confirm the identity of the isolates. Genetic variation was established by AFLP. To determine the antifungal susceptibility profile, the Sensititre™ YeastOne™ assay was used. To develop a species specific PCR primers were designed on the sequenced PCR amplicon from the M. mycetomatis specific PCR. Results By analyzing the ITS, BT and RBP2 regions the isolates were identified as Madurella pseudomycetomatis. The isolates from father and son were similar but not identical to M. pseudomycetomatis from Venezuela and one from an unknown origin. Madurella pseudomycetomatis isolates were inhibited by itraconazole, posaconazole and voriconazole but showed increased MIC values for amphotericin B and fluconazole. They were not inhibited by the echinocandins and 5 flucytosine. The two patients were treated with itraconazole resulting in cure for the father while the son was lost to follow up. The species‐specific PCR developed for M. pseudomyceotmatis was discriminative and specific. Conclusion M. pseudomycetomatis is genetically diverse with same susceptibility profile as M. mycetomatis and causes eumycetoma in Latin America. The M. pseudomycetomatis specific PCR can be used to identify this causative agent to the species level, however, this needs to be validated in an endemic setting.Keywords
Funding Information
- Erasmus Universiteit Rotterdam
This publication has 33 references indexed in Scilit:
- Global Burden of Human Mycetoma: A Systematic Review and Meta-analysisPLoS Neglected Tropical Diseases, 2013
- New Species of Madurella, Causative Agents of Black-Grain MycetomaJournal of Clinical Microbiology, 2012
- Identifying and reducing AFLP genotyping error: an example of tradeoffs when comparing population structure in broadcast spawning versus brooding oystersHeredity, 2012
- In Vitro Susceptibility of Madurella mycetomatis to Posaconazole and TerbinafineAntimicrobial Agents and Chemotherapy, 2011
- Madurella mycetomatis Is Not Susceptible to the Echinocandin Class of Antifungal AgentsAntimicrobial Agents and Chemotherapy, 2010
- Phenotypic and Molecular Characterization ofMadurella pseudomycetomatissp. nov., a Novel Opportunistic Fungus Possibly Causing Black-Grain MycetomaJournal of Clinical Microbiology, 2010
- Incidence and changing pattern of mycetoma in western RajasthanIndian Journal of Pathology and Microbiology, 2008
- Comparison of Two Highly Discriminatory Molecular Fingerprinting Assays for Analysis of Multiple Aspergillus fumigatus Isolates from Patients with Invasive AspergillosisJournal of Clinical Microbiology, 2007
- In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisininJournal of Antimicrobial Chemotherapy, 2007
- In Vitro Susceptibilities of Madurella mycetomatis to Itraconazole and Amphotericin B Assessed by a Modified NCCLS Method and a Viability-Based 2,3-Bis(2-Methoxy-4-Nitro-5- Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2 H - Tetrazolium Hydroxide (XTT) AssayAntimicrobial Agents and Chemotherapy, 2004